On September 23, 2021 Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), a clinical-stage cell therapy company, reported the European Patent Office’s decision to grant patent EP 3,362,470 B1, which was published in the European Patent Bulletin dated September 22, 2021 (Press release, Chimeric Therapeutics, SEP 23, 2021, View Source [SID1234591514]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The granted patent covers certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s clinical-stage CAR T asset, CHM 1101, with patent protection expected until 2036.

Chimeric holds the exclusive worldwide license to develop and commercialize EP 3,362,470 B1 and related patent applications filed in other global territories.

Commenting on Chimeric’s intellectual property position, CEO and Managing Director Jennifer Chow said:

"We are pleased to see the continued advancement of the strong intellectual property portfolio underpinning Chimeric’s CLTX CAR T program, on this occasion in a geography that holds significant market potential."

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.